New viral and non-viral platforms for T-cell engineering

Conference Dates

January 27-31, 2019


FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including:  New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral Production System o Platform development process using Design of Experiment (DOE) methodologies o High-throughput to large scale bioreactor protocols o Cost benefits of this system over current methods  Novel gene editing tools for primary T cells o New potent gene editing tools to increase knock-in and knock-out efficiency o Addressing non-viral delivery barriers through protocol optimization Learning Objectives:  Current industry trends and challenges of cell and gene therapy manufacturing  Benefits of innovative new upstream technologies for virus generation in suspension

76-Poster 41.pdf (300 kB)

This document is currently not available here.